Blood, 15 February 2005, Vol. 105, No. 4, pp. 1549-1551.
Prepublished online as a Blood First Edition Paper on October 14, 2004; DOI 10.1182/blood-2004-08-3328.
 Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Brief report
Marburg I polymorphism of factor VII–activating protease is associated with idiopathic venous thromboembolism
Berthold Hoppe,
Farzaneh Tolou,
Hartmut Radtke,
Holger Kiesewetter,
Thomas Dörner, and
Abdulgabar Salama
From the Institute of Transfusion Medicine, Campus Virchow-Klinikum, Charité—Universitätsmedizin Berlin, Germany.
 |
Abstract
|
|---|
The factor VII–activating protease (FSAP) variant Marburg I is known to attenuate the profibrinolytic system in vitro and was recently shown to be a significant predictor for the evolution and progression of carotid stenosis. The objective of this case-control study was to assess FSAP Marburg I's role in the occurrence of venous thromboembolism (VTE). The frequency of FSAP Marburg I was significantly increased in patients with a history of VTE (17 of 213 patients, 8.0%, P = .014) or idiopathic VTE (12 of 103 patients, 11.7%, P = .002) compared to healthy controls (5 of 213 controls, 2.3%). Logistic regression analysis confirmed FSAP Marburg I to be an independent risk factor for VTE (odds ratio, 3.5; 95% confidence interval [CI], 1.2-10.0) and idiopathic VTE (odds ratio, 6.2; 95% CI, 2.0-18.9).
|
Introduction
|
|---|
Factor VII–activating protease (FSAP) has 2 main functions in coagulation. It was first described as a tissue factor–independent activator of factor VII promoting early steps of the coagulation pathway1 and was later found to contribute to the fibrinolytic pathway by activating prourokinase.2 The Marburg I polymorphism (Gly511Glu) is a frequent variant of FSAP in which the activity toward prourokinase is diminished, while the capacity to activate factor VII is preserved.3 Due to the resulting hemostatic imbalance, it seems likely that FSAP Marburg I may promote the development of thromboembolic diseases. FSAP Marburg I was shown recently to be a significant predictor for the evolution and progression of carotid stenosis,4 but it is unknown whether it plays a role in the occurrence of venous thromboembolism (VTE).
This case-control study was designed to determine whether FSAP Marburg I is associated with an increased risk of VTE.
|
Study design
|
|---|
During May 2003 and May 2004, a total of 239 patients with a history of VTE were admitted to our institution for thrombophilia work-up. Patients were referred from regional hospitals and primary care physicians from Berlin-Brandenburg (Germany). We excluded 21 patients with axillary, mesenteric, or cerebral vein thrombosis because natural history might be different to deep vein thrombosis (DVT). Five patients refused to participate in this study. The remaining 213 patients with objectively confirmed DVT and/or pulmonary embolism (PE) (DVT, n = 151; PE, n = 17; DVT + PE, n = 45) were enrolled. The median interval between VTE and presentation was 9.5 months (range, 0.4-83 months). The clinical characteristics of patients and controls are shown in Table 1. Secondary VTE due to acquired risk factors (immobilization, surgery, trauma, pregnancy, puerperium, malignancy) was present in 51.6% (n = 110) of cases. VTE was defined as idiopathic (n = 103, 48.4%) if it had not occurred during or fewer than 3 months after exposure to one or more acquired risk factors. During the initial examination the following parameters were determined5,6: Factor V 1691G  A (factor V Leiden) and prothrombin (PT) 20210G A; activity of antithrombin (n = 205), protein S (n = 129), and protein C (n = 128); anticardiolipin IgG/IgM (n = 211), and lupus anticoagulants (n = 206). FSAP Marburg I (1601G A) was analyzed retrospectively using the same protocol6 and the following primer pairs: FSAP 1601G/wild-type: forward primer: 5' tggggcctggagtgtgg 3'; reverse primer: 5' ggtgtccattgttggcc 3'; FSAP 1601A/Marburg I: forward primer: 5' tggggcctggagtgtga 3'; reverse primer: 5' ggtgtccattgttggcc 3'. Blood donors (n = 213, controls) from the same geographical area as the patients were recruited by sex/age-stratified sampling (age strata [y]: < 20, 20-29, 30-39, 40-49, 50-59, and  60) according to the distribution of cases. Consecutive donors with no history of VTE were enrolled until the respective sex/age groups reached the number of cases. Controls were tested for factor V 1691G A, PT 20210G A, and FSAP 1601G A. The study was approved by the local ethics committee. All participants gave informed consent.
Statistical analyses included univariate analysis (Fisher exact test) and logistic regression analysis with factor V Leiden, PT 20210G A, and FSAP Marburg I as independent variables. Statistical analyses were performed using SPSS statistics package V.11 (SPSS, Chicago, IL) and GraphPad Prism 4 (GraphPad Software, San Diego, CA).
|
Results and discussion
|
|---|
The laboratory characteristics of patients and controls are shown in Table 2. The overall frequencies of FSAP Marburg I in cases and controls were 8.0% (n = 17) and 2.3% (n = 5), respectively. FSAP Marburg I was independently associated with VTE (odds ratio, 3.5; 95% CI, 1.2-10.0). All carriers of FSAP Marburg I were heterozygous for this variant. Regarding patients with idiopathic VTE, the independent association with FSAP Marburg I was even stronger than that identified for all patients (odds ratio, 6.2; 95% CI, 2.0-18.9). After exclusion of patients who developed idiopathic VTE under hormonal contraception (n = 18), FSAP Marburg I remained independently associated with VTE (odds ratio, 5.7; 95% CI, 1.7-19.6). In patients with secondary VTE (n = 5, 4.5%) due to acquired risk factors, no association with FSAP Marburg I could be demonstrated.
Significant hereditary thrombophilic risk factors other than FSAP Marburg I, for instance, factor V Leiden (n = 54), PT 20210G A (n = 13), factor V Leiden + PT 20210G A (n = 3), factor V Leiden + protein S deficiency (n = 2), protein S deficiency (n = 1), and antithrombin deficiency (n = 1) were found in 74 patients. A history of VTE in relatives of patients with FSAP Marburg I and no other significant hereditary thrombophilic risk factors was found in 4 of 10 cases. The frequencies of carriers of factor V Leiden and PT 20210G A in controls, patients with VTE, and idiopathic VTE (Table 2) are in agreement with previously published data,7-9 reflecting the comparable composition of our collectives.
Based on our data FSAP Marburg I appears to be a candidate for hereditary thrombophilia. However, some details of our study should be discussed. We analyzed prevalent and not incident cases. Thus, there might be a tendency for inadequate recall of past events. This will not influence the accuracy of the detection of FSAP Marburg I and VTE, because both were based on objective findings. However, the recall of circumstances of VTE might be in some cases incomplete, although the majority of patients presented within 1 year after VTE.
The association of FSAP Marburg I with VTE in prevalent cases could be due to a survival bias of this factor. Although this explanation does not seem likely, it cannot be completely ruled out. An additional potential source of bias is the used control group. Blood donors necessarily should have no known underlying diseases, for example, malignancies or autoimmune diseases. However, as these diseases are not likely to influence the genotype frequency of FSAP, our control group seems to be suitable for determining the frequency of FSAP Marburg I in our geographical area.
FSAP Marburg I is a prevalent variant that exhibits an independent association with VTE. Similar to the prevalence of factor V Leiden and PT 20210G A,9 its frequency in the general population is about 2% to 4%.4 Its effect was especially pronounced in patients with idiopathic VTE, who are known to be prone for recurrence of disease.10 However, based on the presented data, no statement about the influence of FSAP Marburg I on the recurrence rate of VTE is possible. This should be the aim of further studies. The possible significance of FSAP Marburg I becomes obvious when one considers that many previously described thrombophilic risk factors were found to be associated with VTE only under certain circumstances, for example, in surgical patients11 or in combination with other thrombophilic risk factors.12-14
Finally, our results might be helpful in understanding the findings of Prandoni et al,15 who described an association between atherosclerosis (carotid plaques) and idiopathic but not secondary VTE and who raised the question whether these 2 conditions might share common risk factors. Interestingly, FSAP Marburg I was initially described as a predictor for the evolution and progression of carotid stenosis,4 and in our study it could be demonstrated to be associated with idiopathic but not with secondary VTE (Table 2).
Larger studies are needed to conclusively determine the importance of FSAP Marburg I in VTE.
|
Acknowledgements
|
|---|
This work is dedicated to my father, Prof Dr Immo Hoppe.
We thank Gisela Diederich for excellent technical assistance.
|
Footnotes
|
|---|
Submitted August 27, 2004;
accepted October 13, 2004.
Prepublished online as Blood First Edition Paper, October 14, 2004; DOI 10.1182/blood-2004-08-3328.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Berthold Hoppe; Institute of Transfusion Medicine, Campus Virchow-Klinikum, Charité—Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany; e-mail: berthold.hoppe{at}charite.de.
|
References
|
|---|
- Romisch J, Feussner A, Vermohlen S, Stohr HA. A protease isolated from human plasma activating factor VII independent of tissue factor. Blood Coagul Fibrinolysis. 1999;10: 471-479.[Medline]
[Order article via Infotrieve]
- Romisch J, Vermohlen S, Feussner A, Stohr H. The FVII activating protease cleaves single-chain plasminogen activators. Haemostasis. 1999;29: 292-299.[CrossRef][Medline]
[Order article via Infotrieve]
- Roemisch J, Feussner A, Nerlich C, Stoehr HA, Weimer T. The frequent Marburg I polymorphism impairs the pro-urokinase activating potency of the factor VII activating protease (FSAP). Blood Coagul Fibrinolysis. 2002;13: 433-441.[CrossRef][Medline]
[Order article via Infotrieve]
- Willeit J, Kiechl S, Weimer T, et al. Marburg I polymorphism of factor VII-activating protease: a prominent risk predictor of carotid stenosis. Circulation. 2003;107: 667-670.[CrossRef][Medline]
[Order article via Infotrieve]
- Hundsdoerfer P, Vetter B, Stover B, et al. Homozygous and double heterozygous factor V Leiden and factor II G20210A genotypes predispose infants to thromboembolism but are not associated with an increase of foetal loss. Thromb Haemost. 2003;90: 628-635.[Medline]
[Order article via Infotrieve]
- Hoppe B, Heymann GA, Koscielny J, Hellstern P, Kiesewetter H, Salama A. Screening for multiple hereditary hypercoagulability factors using the amplification refractory mutation system. Thromb Res. 2003;111: 115-120.[Medline]
[Order article via Infotrieve]
- Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene, DURAC Trial Study Group: duration of anticoagulation. Thromb Haemost. 1999;81: 684-689.[Medline]
[Order article via Infotrieve]
- Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348: 1425-1434.[Abstract/Free Full Text]
- Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood. 2000;95: 1517-1532.[Free Full Text]
- Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999; 340: 901-907.[Abstract/Free Full Text]
- Philipp CS, Dilley A, Saidi P, et al. Deletion polymorphism in the angiotensin-converting enzyme gene as a thrombophilic risk factor after hip arthroplasty. Thromb Haemost. 1998;80: 869-873.[Medline]
[Order article via Infotrieve]
- Segui R, Estelles A, Mira Y, et al. PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. Br J Haematol. 2000;111: 122-128.[CrossRef][Medline]
[Order article via Infotrieve]
- Perez-Ceballos E, Corral J, Alberca I, et al. Prothrombin A19911G and G20210A polymorphisms' role in thrombosis. Br J Haematol. 2002;118: 610-614.[CrossRef][Medline]
[Order article via Infotrieve]
- Folsom AR, Cushman M, Tsai MY, et al. A prospective study of venous thromboembolism in relation to factor V Leiden and related factors. Blood. 2002;99: 2720-2725.[Abstract/Free Full Text]
- Prandoni P, Bilora F, Marchiori A, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med. 2003;348: 1435-1441.[Abstract/Free Full Text]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Letter in Blood Online:
-
The Marburg I polymorphism of factor VII-activating protease is not associated with venous thrombosis
- Rick van Minkelen, Marieke C. H. de Visser, Hans L. Vos, Rogier M. Bertina, Frits R. Rosendaal, Berthold Hoppe, Guido A. Heymann, Hartmut Radtke, Holger Kiesewetter, Thomas Dörner, and Abdulgabar Salama
Blood 2005 105: 4898-4899.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
N. L. Smith, L. A. Hindorff, S. R. Heckbert, R. N. Lemaitre, K. D. Marciante, K. Rice, T. Lumley, J. C. Bis, K. L. Wiggins, F. R. Rosendaal, et al.
Association of Genetic Variations With Nonfatal Venous Thrombosis in Postmenopausal Women
JAMA,
February 7, 2007;
297(5):
489 - 498.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Sedding, J.-M. Daniel, L. Muhl, K. Hersemeyer, H. Brunsch, B. Kemkes-Matthes, R. C. Braun-Dullaeus, H. Tillmanns, T. Weimer, K. T. Preissner, et al.
The G534E polymorphism of the gene encoding the factor VII-activating protease is associated with cardiovascular risk due to increased neointima formation
J. Exp. Med.,
December 25, 2006;
203(13):
2801 - 2807.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Franchi, I. Martinelli, E. Biguzzi, P. Bucciarelli, and P. M. Mannucci
Marburg I polymorphism of factor VII-activating protease and risk of venous thromboembolism
Blood,
February 15, 2006;
107(4):
1731 - 1731.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. van Minkelen, M. C. H. de Visser, H. L. Vos, R. M. Bertina, F. R. Rosendaal, B. Hoppe, G. A. Heymann, H. Radtke, H. Kiesewetter, T. Dorner, et al.
The Marburg I polymorphism of factor VII-activating protease is not associated with venous thrombosis
Blood,
June 15, 2005;
105(12):
4898 - 4899.
[Full Text]
[PDF]
|
|
|
|
|
Top
Abstract
Introduction